{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT02888106: Phase 2 Interventional Completed Chronic Viral Hepatitis B With Delta-agent
(2016)
Source URL:
Class:
PROTEIN
HBVPRES/2-48CONS-MYR (known as Bulevirtide or Myrcludex B) was developed as an agent bind and inactivate the hepatocyte surface protein sodium taurocholate cotransporting polypeptide (SLC10A1 or NTCP). By blocking NTCP, the drug misdirects hepatitis B virus (HBV) and co-infecting hepatitis D virus (HDV) to an unproductive pathway and thereby prevents infection of the cell. Because NTCP is involved in the bile acid transport cycle, the blockade of this target by myrcludex B can potentially be used for the treatment of various metabolic and inflammatory diseases. Myrcludex B is going to participate in phase 3 trial for patients with chronic hepatitis D, however, the study is not yet recruited. The drug successfully completed phase II clinical trial for the patients with chronic hepatitis B and D. In addition, myrcludex B has been studied during preclinical research as a potential treatment of dyslipidemias, non-alcoholic steatohepatitis; primary biliary cirrhosis.
Status:
Investigational
Source:
NCT04456621: Not Applicable Interventional Completed Local Control Rate
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02494154: Not Applicable Interventional Unknown status Respiratory Failure
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT04251156: Phase 3 Human clinical trial Completed Overweight
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02356978: Not Applicable Interventional Unknown status Crigler Najjar Syndrome
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03708211: Phase 1 Interventional Completed Neoplasms, Advanced Solid
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00791570: Phase 1 Interventional Completed Neovascular Maculopathy
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02501577: Not Applicable Interventional Unknown status Intubation; Difficult
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01373450: Phase 1 Interventional Completed Type 2 Diabetes Mellitus
(2011)
Source URL:
Class:
PROTEIN
